Fact CheckerSign in

NCT06601465RecruitingPhase 2

COgnitioN With VERiciGuat Evaluation in Heart Failure

CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure

Source: ClinicalTrials.gov · Last updated 25 Aug 2026

Brief summary (registry, in English)

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
120 (estimated)
First submitted
6 Sept 2024
Start date
3 Jun 2025
Primary completion date
16 Jul 2028
Lead sponsor
University of Alberta
NCT number
NCT06601465

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 120
  • From 3 Jun 2025 to the primary completion date, 16 Jul 2028
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
  • General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures \[coronary angioplasty and/or surgical revascularization in the previous 3 months\], cancer/malignancy, or with severe dementia).

Other illness

  • CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
  • Patients with allergies to the study products.

Other

  • Unable to undergo CMR imaging or brain MRI.
  • Patients currently hospitalized.

Who the study is looking for

  • Adult patients
  • Established chronic heart failure (≥ 6 months)
  • Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Of Calgary
Coordinator of this site? Confirm its status
CalgaryCanadaRecruiting
University of Alberta
Coordinator of this site? Confirm its status
EdmontonCanadaRecruiting
McGill University Health Center
Coordinator of this site? Confirm its status
MontrealCanadaNot yet recruiting
University of Ottawa
Coordinator of this site? Confirm its status
OttawaCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.